Fertility Preservation in Breast Cancer Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

March 31, 2018

Study Completion Date

December 31, 2024

Conditions
Breast NeoplasmsFertility
Interventions
DRUG

Letrozole

"Patients start ovarian stimulation protocol according to their menstrual cycle phase at enrollment (standard or random start). Ovarian stimulation includes gonadotropins administration in a GnRH antagonist protocol Standard Protocol: letrozole is orally administered 2 tablets per day (2,5mgx2/d) from cycle day 2 throughout the ovarian stimulation with gonadotropins protocol until ovulation triggering. GnRH antagonist is administered as soon as at least one follicle reaches 14 mm.~Random start protocol: letrozole is administered throughout the stimulation together with gonadotropins and GnRH antagonist, until ovulation triggering.~Oocytes are collected 36h after ovulation triggering. All patients receive GnRH antagonist after oocyte retrieval for 3-7 days or until chemotherapy starts, to induce luteolysis."

Trial Locations (1)

1070

Erasme-CUB, Brussels

All Listed Sponsors
lead

Erasme University Hospital

OTHER

NCT02661932 - Fertility Preservation in Breast Cancer Patients | Biotech Hunter | Biotech Hunter